# Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes

> **NCT01511172** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 145 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** metformin
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** glimepiride

## Key facts

- **NCT ID:** NCT01511172
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01511172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01511172, "Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01511172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*